Journal
MOLECULES
Volume 23, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/molecules23030581
Keywords
targeted alpha therapy; nuclear recoil; in vivo generators; radium; Ra-223; actinium; astatine; bismuth; alpha particle; decay
Funding
- Health Research Agency of the Czech Republic [NV16-30544A]
- Russian Foundation for Basic Research
- Moscow city government [15-33-70004 mol_a_mos]
- Technology Agency of the Czech Republic [TJ01000334]
- EU
- Ministry of Education Youth and Sports of the Czech Republic [CZ.02.1.01/0.0/0.0/15_003/0000464]
Ask authors/readers for more resources
This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like At-211, Ra-223, Ac-225/Bi-213, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available